Compare SHASUN PHARMA with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA LUPIN SHASUN PHARMA/
LUPIN
 
P/E (TTM) x 123.9 48.0 258.1% View Chart
P/BV x 8.5 4.4 193.3% View Chart
Dividend Yield % 0.2 0.5 47.5%  

Financials

 SHASUN PHARMA   LUPIN
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
LUPIN
Mar-20
SHASUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs94882 10.7%   
Low Rs46505 9.0%   
Sales per share (Unadj.) Rs214.2339.4 63.1%  
Earnings per share (Unadj.) Rs5.3-5.9 -89.7%  
Cash flow per share (Unadj.) Rs15.815.5 102.3%  
Dividends per share (Unadj.) Rs1.006.00 16.7%  
Dividend yield (eoy) %1.40.9 165.4%  
Book value per share (Unadj.) Rs53.3276.7 19.3%  
Shares outstanding (eoy) m56.62453.00 12.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 16.0%   
Avg P/E ratio x13.1-116.6 -11.2%  
P/CF ratio (eoy) x4.444.8 9.9%  
Price / Book Value ratio x1.32.5 52.3%  
Dividend payout %18.7-100.9 -18.6%   
Avg Mkt Cap Rs m3,958314,201 1.3%   
No. of employees `000NA18.3 0.0%   
Total wages/salary Rs m2,16429,868 7.2%   
Avg. sales/employee Rs ThNM8,400.6-  
Avg. wages/employee Rs ThNM1,632.0-  
Avg. net profit/employee Rs ThNM-147.2-  
INCOME DATA
Net Sales Rs m12,127153,748 7.9%  
Other income Rs m2294,838 4.7%   
Total revenues Rs m12,356158,585 7.8%   
Gross profit Rs m1,00924,849 4.1%  
Depreciation Rs m5949,702 6.1%   
Interest Rs m4153,630 11.4%   
Profit before tax Rs m23016,355 1.4%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 -0.8%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m-7311,571 -0.6%   
Profit after tax Rs m302-2,694 -11.2%  
Gross profit margin %8.316.2 51.5%  
Effective tax rate %-31.770.8 -44.7%   
Net profit margin %2.5-1.8 -142.2%  
BALANCE SHEET DATA
Current assets Rs m6,884154,132 4.5%   
Current liabilities Rs m8,45692,252 9.2%   
Net working cap to sales %-13.040.2 -32.2%  
Current ratio x0.81.7 48.7%  
Inventory Days Days6282 75.1%  
Debtors Days Days108129 83.2%  
Net fixed assets Rs m4,97089,082 5.6%   
Share capital Rs m113906 12.5%   
"Free" reserves Rs m2,875124,461 2.3%   
Net worth Rs m3,020125,367 2.4%   
Long term debt Rs m1,81717,933 10.1%   
Total assets Rs m13,347249,839 5.3%  
Interest coverage x1.65.5 28.2%   
Debt to equity ratio x0.60.1 420.7%  
Sales to assets ratio x0.90.6 147.6%   
Return on assets %5.40.4 1,434.5%  
Return on equity %10.0-2.1 -465.5%  
Return on capital %13.38.7 152.6%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84351,450 11.4%   
Fx outflow Rs m2,17319,470 11.2%   
Net fx Rs m3,66931,980 11.5%   
CASH FLOW
From Operations Rs m39814,688 2.7%  
From Investments Rs m-1,63511,070 -14.8%  
From Financial Activity Rs m1,309-8,906 -14.7%  
Net Cashflow Rs m7116,853 0.4%  

Share Holding

Indian Promoters % 39.2 46.6 84.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 31.9 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.1 392.1%  
Shareholders   20,750 98,259 21.1%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT PHARMOVA   

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Maruti Extends Production Shutdown, Avenue Supermarts Q4 Results, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 296 points (up 0.6%).

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS